Sorry, you need to enable JavaScript to visit this website.

CELEBREX (celecoxib) Contraindications

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Cliquez ici pour savoir comment nous avons réagi.


CELEBREX (celecoxib) is contraindicated in:

  • The peri-operative setting of Coronary Artery Bypass Graft Surgery (CABG). Although CELEBREX has NOT been studied in this patient population, a selective COX-2 inhibitor NSAID studied in such a setting has led to an increased incidence of cardiovascular/thromboembolic events, deep surgical infections and sternal wound complications (see CLINICAL TRIALS – Cardiovascular Safety).
  • The third trimester of pregnancy, because of risk of premature closure of the ductus arteriosus and prolonged parturition.
  • Women who are breastfeeding, because of the potential for serious adverse reactions in nursing infants.
  • Severe uncontrolled heart failure.
  • Known hypersensitivity to celecoxib or to any of the components/excipients.
  • Demonstrated allergic-type reactions to sulfonamides.
  • History of asthma, urticaria, or allergic-type reactions after taking Acetylsalicylic Acid (ASA) or other NSAIDs (i.e. complete or partial syndrome of ASA-intolerance - rhinosinusitis, urticaria/angioedema, nasal polyps, asthma). Fatal anaphylactoid reactions have occurred in such individuals. Individuals with the above medical problems are at risk of a severe reaction even if they have taken NSAIDs in the past without any adverse reaction. The potential for cross-reactivity between different NSAIDs must be kept in mind (see WARNINGS AND PRECAUTIONS - Hypersensitivity Reactions - Anaphylactoid Reactions).
  • Active gastric / duodenal / peptic ulcer, active gastrointestinal bleeding.
  • Cerebrovascular bleedings.
  • Inflammatory bowel disease.
  • Severe liver impairment or active liver disease.
  • Severe renal impairment (creatinine clearance <30 mL/min or 0.5 mL/sec) or deteriorating renal disease (individuals with lesser degrees of renal impairment are at risk of deterioration of their renal function when prescribed NSAIDs and must be monitored) (see WARNINGS AND PRECAUTIONS - Renal).
  • Known hyperkalemia (see WARNINGS AND PRECAUTIONS - Renal - Fluid and Electrolyte Balance).
  • Safety and efficacy of CELEBREX have not been established in the paediatric population under 18 years of age.

What's New

No Current Announcements.

Other Resources

Contact Pfizer Medical Information

Report an Adverse Event
1 866 723-7111